The 22q13 deletion syndrome is associated with global developmental delay, absent or delayed speech, and generalised hypotonia. In this study, the size and nature of 22q13 deletions (n ¼ 9) were studied in detail by high-resolution chromosome specific array-based comparative genomic hybridisation (array CGH). The deletion sizes varied considerably between the different patients, that is, the largest deletion spanning 8.4 Mb with the breakpoint mapping to 22q13.2 and the smallest deletion spanning 3.3 Mb with the breakpoint mapping to 22q13.31. In one case, a unique subtelomeric 3.9 Mb deletion associated with a 2.0 Mb duplication of 22q13 was observed, adding to a growing number of similar cases identified for other chromosome ends. Remarkably, this patient had signs suggestive of retinitis pigmentosa, which has never been reported before in the 22q13 deletion syndrome. The identification of two pairs of recurrent proximal breakpoints on 22q13 suggests that these specific regions may be prone to recombination, due to yet unknown genome architectural features. In addition to the copy number changes on 22q13, a duplication of B330 kb on 22q11.1 was observed and shown to be a genetic large-scale copy number variation without clinical consequences. The current study failed to reveal relationships between the clinical features and the deletion sizes. Global developmental delay and absent or severely delayed speech were observed in all patients, whereas hypotonia was present in 89% of the cases (8/9). This study underscores the utility of array CGH for characterising the size and nature of subtelomeric deletions, such as monosomy 22q13, and underlines the considerable variability in deletion size in the 22q13 deletion syndrome regardless of the clinical phenotype.
Introduction
Subtelomeric deletions are a common cause of mental retardation. 1, 2 In recent years, screening of subtelomeres for copy number changes in mentally retarded patients has resulted in the recognition of new distinct clinical entities, based on monosomy 1q, 2q, 9q, 14q, and 22q (reviewed in Vries et al 1 ) The latter entity is also referred to as the 22q13 deletion syndrome, of which to date at least 100 cases have been reported. 3 -6 Common features associated with this syndrome are mild-to-severe global developmental delay, absent or delayed speech, generalised hypotonia, and minor anomalies including dolichocephaly, ptosis, abnormal ears, relatively large hands, and dysplastic toenails. 5 Here we describe a series of nine patients with monosomy 22q13 in which the size and the nature of the chromosome 22 deletions were studied in detail by highresolution chromosome-specific array-based comparative genomic hybridisation (array CGH). 7 
Materials and methods

Patients and DNA samples
In total, nine patients with subtelomeric deletions of 22q13 were included in this study. Three cases were previously published (case 2, 8 case 7 9 and case 9 10 ). DNA samples of the patients were derived from different clinical centres in France, Ireland, the United Kingdom, and the Netherlands (Nijmegen). Clinical information on the patients was obtained from the referring physician. DNA samples of all patients were analysed using array CGH. In one patient (case 3), the 22qter deletion was initially identified by routine chromosome analysis at a 550-band level and confirmed by fluorescence in situ hybridisation (FISH) [46, XY, del (22) 
Results
Seven patients with a submicroscopic 22qter deletion, one patient with an unbalanced translocation and one patient with a microscopically visible 22qter deletion were studied. In Table 1 , the main characteristics of the patients are summarised. In addition, minor facial dysmorphisms were noted (Figure 1 ). High-resolution chromosome 22-specific array CGH confirmed the known copy number changes in all cases and delineated the specific aberrations in detail. Figure 2 shows two examples of chromosome 22 array CGH profiles. All deletions analysed included the most telomeric clones. Interstitial deletions in the subtelomeric region of the long arm of chromosome 22 were not observed. The deletion sizes identified in this study varied considerably between the different patients, that is, the largest deletion spanning 8.4 Mb with breakpoint mapping to 22q13.2qter (68 clones, case 1) and the smallest deletion spanning 3.3 Mb with breakpoints mapping to 22q13.31qter (27 clones, case 9) ( Figure 3 ). Identical proximal breakpoints were localised in cases 2 and 3 (between RP11-786O06 and RP11-236I15) and cases 5 and 6 (between RP11-766K21 and RP11-49A20), resulting in deletion sizes of 7.7 and 5.9 Mb, respectively. In case 3, a del (22) . Array CGH analysis revealed a 6.6 Mb deletion at 22q13.31qter. In case 7, a deletion of 5.0 Mb was identified, whereas in case 8 the deletion spanned 3.9 Mb. The latter 22q13 deletion was associated with a duplication of 2.0 Mb, including 13 clones adjacent to the deleted region ( Figure 2b ). In addition to these subtelomeric copy number alterations, a duplication of B330 kb on 22q11.1 was detected in the same patient. Duplications in the same region next to the centromere were identified in two other cases in this series (cases 4 and 7). In the control panel of 72 normal individuals tested by a tiling resolution genome-wide BAC array, copy number Characterising 22q13 deletions by array CGH DA Koolen et al gain of the same region was observed in five individuals, whereas loss of the chromosomal segment was seen in 21 controls (de Vries, submitted).
Discussion
For detailed analyses of patients with known 22q13 deletions, a tiling resolution array was constructed with a 1.7-fold coverage of the long arm of chromosome 22. Buckley et al 12 demonstrated the utility of such a comprehensive chromosome 22 array by profiling acral melanoma, dermatofibrosarcoma, DiGeorge syndrome, and neurofibromatosis 2. The chromosome 22 tiling resolution array had an average clone spacing of 100 kb, resulting in a resolution that is 30 times higher than highresolution karyotyping. The array did not cover the most telomeric 635 kb of the chromosome, which includes the gene SHANK3/ProSAP2. Haploinsufficiency of this gene has been proposed to be responsible for the major neurological features of the 22q13 deletion syndrome. 6, 13, 14 However, FISH analysis using subtelomeric clones, confirmed the extension of all deletions found till the subtelomeric region.
In the present study, a considerable difference in deletion sizes was noted, which is in accordance with the results of Luciani et al 3 which showed an extremely variable 22qter deletion size, extending from 160 kb to 9 Mb. Interestingly, proposed a premeiotic model in which a terminally deleted chromosome is generated in the germ line and passes through at least one breakage -fusion -bridge cycle in which uncapped sister chromatids are fused by nonhomologous end joining (NHEJ), resulting in gametes with terminal deletions associated with cryptic interrupted inverted duplications. The identification of recurrent proximal breakpoints in cases 2 and 3 (between RP11-786O06 and RP11-236I15) and cases 5 and 6 (between RP11-564B15 and RP11-673D06), suggests that these regions may be prone to recombination, due to the presence of yet unknown genome architectural features. Segmental duplications were present at or close to the recurrent breakpoints and also to the other, nonrecurrent breakpoints in our series. To a large extent, chromosome rearrangement breakpoints are located in intervals containing complex genomic architecture, such as AT-rich palindromes or low-copy repearts (LCRs). 20 Through the process of NAHR, LCRs can lead to translocations, inversions, duplications and interstitial deletions. 21 However, the mechanisms for generating and/or stabilising terminally deleted chromosomes are poorly understood. NEHJ, possibly stimulated by LCRs or other repetitive sequences, may be one of the causative mechanisms for the terminal 22q13 deletions in our series. In addition to the known 22qter deletions, a submicroscopic duplication on 22q11.1 next to the centromere was identified in three cases (cases 4, 7 and 8). In the control population of 72 normal individuals, copy number gains in the same region were identified in five individuals, whereas losses were observed in 21 controls (de Vries; submitted), indicating that this anomaly represents a LCV. This LCV at 22q11.1 was previously reported by Sebat et al 22 (http://projects.tcag.ca/variation/) and stresses the variation of the human genome and the importance of parental and control analysis in case a submicroscopic alteration is identified. Three hidden states represent normal (empty), loss (LOSS) and gain (GAIN) conditions. Individual clones that did not pass quality control criteria were excluded (EXCL).
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In the current study, no relation between clinical features and deletion size could be observed. The clinical features observed were consistent with the common clinical phenotype associated with the 22q13 deletion syndrome, 5 although dolichocephaly and ptosis were not found in the current study. Global developmental delay and absent or severely delayed speech were observed in all patients. Hypotonia was present in 89% of the cases (8/9). A pointed chin was present in cases 1 and 4 -7. Wilson et al 6 previously suggested a candidate gene for this feature in the proximal region of 22q13, however this could not be confirmed in our series. In addition, in case 8, ophthalmic assessment showed myopia and salt-and-pepper retinal changes suggestive of retinitis pigmentosa. These eye anomalies, which have not been reported in the 22q13 deletion syndrome before, are possibly attributable to the 2 Mb 22q13.31 duplication in this patient. Relationship between the deletion size and clinical features could not be observed. However, case 9 with the smallest 22q13 deletion (3.3 Mb), did not show any of the dysmorphic features commonly described in the 22q13 deletion syndrome. Facial dysmorphic features in this patient included upslanting palpebral fissures, a moderate hypertrophic nasal root, and thick lips. 10 These findings underline the study of Wilson et al, in which no significant correlation with the size of the deletion could be demonstrated for most clinical features and support the idea that a gene in the 3.3 Mb minimal deleted region (notably SHANK3/ ProSAP2) may be the major candidate gene in the 22q13 deletion syndrome. 3 -6 In conclusion, this study underscores the utility of array CGH for further characterisation of the size and nature of subtelomeric deletions. In addition, these results confirm the considerable differences in deletion size observed in patients with the 22q13 deletion syndrome, regardless of the clinical phenotype.
